Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aerosol Cyclosporine for Prevention of Lung Rejection
NCT00268515Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Apr 1998
- Modality
- Peptides, Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in lung transplant rejection comparing Cyclosporine Aerosol with Placebo Aerosol (2 arms). Primary endpoint: Rate of histologic acute rejection (Grade >= 2) at 2 years. Started Apr 1998; status: completed.
02
Drugs
cyclosporine
03
Conditions
lung transplant rejection
Beyond the preview
Go deeper on NCT00268515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00268515.